<SEC-DOCUMENT>0001628280-16-021583.txt : 20161121
<SEC-HEADER>0001628280-16-021583.hdr.sgml : 20161121
<ACCEPTANCE-DATETIME>20161121163451
ACCESSION NUMBER:		0001628280-16-021583
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161117
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161121
DATE AS OF CHANGE:		20161121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VERACYTE, INC.
		CENTRAL INDEX KEY:			0001384101
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				205455398
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36156
		FILM NUMBER:		162010671

	BUSINESS ADDRESS:	
		STREET 1:		6000 SHORELINE COURT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 243-6300

	MAIL ADDRESS:	
		STREET 1:		6000 SHORELINE COURT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALDEROME INC
		DATE OF NAME CHANGE:	20061219
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vcyt-8k11216announcement.htm
<DESCRIPTION>VCYT-11.21.16-8K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA6BBA3BC7A3EFD8C712F74C8DA4A0527"></a></div><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;"><hr></div><div style="line-height:173%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:173%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:173%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C.  20549</font></div><div style="line-height:173%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:173%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:173%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:173%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:173%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:173%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:173%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported):  November 17, 2016</font></div><div style="line-height:173%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:173%;text-align:center;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;font-weight:bold;">VERACYTE, INC.</font></div><div style="line-height:144%;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.35897435897436%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:3%;"></td><td style="width:32%;"></td><td style="width:3%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DELAWARE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-36156</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20-5455398</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:18px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.35897435897436%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:38%;"></td><td style="width:24%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6000 Shoreline Court, Suite&#160;300, South San Francisco, California</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">94080</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:173%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code:  </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(650) 243-6300</font></div><div style="line-height:173%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div><div style="line-height:173%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former name or former address, if changed since last report.)</font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.35897435897436%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Wingdings;font-size:9.5pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Wingdings;font-size:9.5pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Wingdings;font-size:9.5pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Wingdings;font-size:9.5pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:144%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;"><hr></div><div><br></div><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.02 Departure </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)  On November 21, 2016, Veracyte, Inc. (the "Company") announced that Keith Kennedy has been appointed by the Company's Board of Directors to serve as the Company's chief financial officer, effective December 6, 2016. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Kennedy, age 46, served as president and chief executive officer of MCG Capital Corporation, a commercial finance company, from 2014 to 2015 and previously served as chief financial officer, chief accounting officer and treasurer of MCG Capital from 2012 to 2014.  From 2011 to 2012, Mr. Kennedy served as healthcare executive-in-residence at Arlington Capital Partners.  From 2002 to 2009, Mr. Kennedy served as a managing director at GE Capital, Inc.  From 1999 to 2002, Mr. Kennedy worked as a manager of transaction services at Ernst &amp; Young LLP.  Mr. Kennedy served in the U.S. Air Force from 1992 to 1996.  Mr. Kennedy received his M.B.A. from the College of William &amp; Mary and a Bachelor of Science with high distinction from Indiana University.  Mr. Kennedy is a chartered financial analyst and certified public accountant.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no arrangements or understandings between Mr. Kennedy and any other persons pursuant to which he was appointed as chief financial officer. There is no family relationship between Mr. Kennedy and any director, officer, or person nominated or chosen by the Company to become a director or officer of the Company. The Company has not entered into any transactions with Mr. Kennedy that would require disclosure pursuant to Item 404(a) of Regulation S-K under the Exchange Act.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Kennedy's employment will be on at at-will basis.  As the Company&#8217;s chief financial officer, Mr. Kennedy will:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">receive an annual base salary of $400,000 per year;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be eligible to participate in the Veracyte 2017 Bonus Program with a target bonus of 50% of eligible annual earnings to be earned based on factors such as the Company&#8217;s performance and his individual performance, and subject to the approval of the Company&#8217;s Compensation Committee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be granted the option to purchase 100,000 shares of the Company's common stock at a price per share equal to the fair market value of the Company's common stock on the date of the grant, which will be the date of commencement of employment, with vesting beginning on the first anniversary of employment, with 1/36 of the shares vesting each month for the following 36 months;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be granted 25,000 restricted share units that will vest on the one-year anniversary of the commencement of employment; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be eligible to participate in the Company&#8217;s benefits programs, subject to the terms and conditions of each program; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for up to one year from commencement of employment, the Company will reimburse reasonable travel expenses to his state of residence and relocation costs.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon employment, Mr. Kennedy will enter into Change of Control and Severance Agreement, which will provide for certain payments and benefits in the event of termination of employment with the Company in connection with a change in control of the Company and will be in the same form as the Company&#8217;s change of control and severance agreements with its other executive officers, a description of which is set forth in the Company&#8217;s proxy statement on Schedule 14A for its annual meeting of stockholders held on June 17, 2016 under the caption &#8220;Executive Compensation&#8212;Termination-based Compensation&#8221; and is incorporated herein by reference. In accordance with the Company&#8217;s customary practice, the Company and Mr. Kennedy will also enter into an Indemnification Agreement, which will require the Company to indemnify him against certain liabilities that may arise in connection with his status or service as an officer. The foregoing description is qualified in its entirety by the full text of the Change of Control and Severance Agreement to be entered into with Mr. Kennedy, which will be filed as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ending December 31, 2016 and&#160;the form of Indemnification Agreement, which has been filed as Exhibit 10.1 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2015 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-191282), as amended, declared effective on October 29, 2013).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A copy of the press release issued by the Company announcing the appointment of Mr. Kennedy is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01  Financial Statements and Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;Exhibits</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:87%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release issued by Veracyte,&#160;Inc. dated November 21, 2016.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:173%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:173%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:173%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:173%;text-align:left;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;"></font><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.35897435897436%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:9%;"></td><td style="width:52%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: November 21, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VERACYTE,&#160;INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Julie A. Brooks</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Julie A. Brooks</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Counsel</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:173%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:173%;text-align:left;padding-left:384px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vcyt-8k111716exhibit991.htm
<DESCRIPTION>VCYT - 8K 11.17.16 - EX99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s69B68F636BC6316AC8077A03650EE953"></a></div><div></div><div><br></div><div style="line-height:138%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exhibit 99.1</font></div><div style="line-height:138%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:center;"><img src="vcyt8k111716exhibit99.jpg" alt="vcyt8k111716exhibit99.jpg" style="font-family:Arial;height:81px;width:150px;"></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For Immediate Release</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Veracyte Appoints Keith Kennedy as Chief Financial Officer</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">SOUTH SAN FRANCISCO, Calif., November 21, 2016 --- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced the appointment of Keith Kennedy as chief financial officer. Mr. Kennedy, the former president and chief executive officer of MCG Capital Corporation (NASDAQ: MCGC), will join Veracyte effective December 6, 2016.</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8220;With three commercial products and a strong financial foundation, we believe Veracyte is well-positioned for profitable growth as we target a combined market opportunity of over $2 billion,&#8221; said Bonnie Anderson, the company&#8217;s president and chief executive officer. &#8220;Keith&#8217;s deep expertise in financial strategy and operations, coupled with his knowledge of the healthcare sector, will support our efforts to transform disease diagnosis while delivering exceptional value to our shareholders.&#8221; </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mr. Kennedy joins Veracyte with over 20 years of executive experience in finance. As president and chief executive officer of MCG Capital, Mr. Kennedy led strategy and operations for the publicly held commercial finance company and assumed various board roles and oversight responsibilities for its portfolio companies in health care and other industries. He led MCG Capital&#8217;s successful sale to PennantPark Floating Rate Capital Ltd. in 2015 and consulted for PennantPark Investment Advisors, LLC after the sale. Mr. Kennedy previously served as MCG&#8217;s chief financial officer, chief accounting officer and treasurer. Prior to MCG, Mr. Kennedy served as a healthcare executive-in-residence at Arlington Capital Partners and a managing director at GE Capital. Prior to GE Capital, Mr. Kennedy worked for Ernst &amp; Young LLP and served as an officer in the U.S. Air Force. Mr. Kennedy received his M.B.A. from The College of William &amp; Mary and Bachelor of Science with high distinction from Indiana University. Mr. Kennedy is a chartered financial analyst and certified public accountant. </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">About&#160;Veracyte</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Veracyte&#160;(NASDAQ: VCYT) is pioneering the field of molecular cytology, offering genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte&#8217;s Afirma</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;Thyroid FNA Analysis centers on the proprietary Afirma Gene Expression Classifier (GEC) and is becoming a new standard of care in thyroid nodule assessment. The Afirma test is recommended in leading practice guidelines and is covered for 185 million lives in&#160;the United States, including through&#160;Medicare and many </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">commercial insurance plans.&#160;Veracyte&#160;is expanding its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In&#160;2015, the company launched the Percepta</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#160;Bronchial Genomic Classifier, a test to evaluate patients with lung nodules that are suspicious for cancer, which has already received draft Medicare coverage.&#160;In October 2016, Veracyte launched its second pulmonology product, the Envisia&#8482; Genomic Classifier, to improve diagnosis of interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cautionary Note Regarding Forward-Looking Statements&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Arial;font-size:10pt;">This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding Mr. Kennedy&#8217;s expected start date, our belief that we are well positioned for profitable growth as we target a combined market opportunity of over $2 billion and Mr. Kennedy&#8217;s expected support for our efforts to transform disease diagnosis while delivering exceptional value to our shareholders. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: unanticipated changes in the timing of Mr. Kennedy&#8217;s start date; the applicability of clinical results to actual outcomes; laws and regulations applicable to our business, including potential regulation by the&#160;Food and Drug Administration&#160;or other regulatory bodies;&#160;the size of the market opportunity for our products; our ability to successfully achieve adoption of and reimbursement for our products; the amount by which use of our products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; the timing and publication of clinical study results; and other risks set forth in the company's filings with the&#160;Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended&#160;September 30, 2016. These forward-looking statements speak only as of the date hereof and&#160;Veracyte&#160;specifically disclaims any obligation to update these forward-looking statements.</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Source: Veracyte</font></div><div style="line-height:138%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">#&#160; #&#160; #</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Media:</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tracy Morris&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">650-380-4413 </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tracy.Morris@Veracyte.com</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Investors:</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pam Lord&#160; <br>Canale Communications</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">619-849-6003</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">pam@canalecomm.com </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>vcyt8k111716exhibit99.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 vcyt8k111716exhibit99.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   .Q%$2
M  0    !   .Q        8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( &  K@,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4[E8!@?4&G445\*?:!1110 4444 %%%% !1110 4444 %%%% !1110!\?_\
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M-LVH8##NO6^26[?9?Y]#\^RG*:^85U0HKU?1+N_ZU-3_ ()T?\$Z//\ L'Q
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CI\&D:?!:VL,=O:VL:Q0Q1J%2)%&%4 <     5-117*(__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
